Similares a Mepolizumab Reduced COPD Hospitalizations in Eosinophilic Disease | ATS 2026 With Gerard Criner, MD

20 vecinos (text_768) · 113 views · HCPLive · Estados Unidos


★	Mepolizumab Reduced COPD Hospitalizations in Eosinophilic Disease \| ATS 2026 With Gerard Criner, MD	HCPLive @hcplivenews	113	Estados Unidos
1	Mepolizumab Add-On Reduces COPD Exacerbations in Triple-Therapy Patients \| ATS 2026	HCPLive @hcplivenews	1.2K	Estados Unidos	95
18	Efdoralprin Alfa Normalizes Alpha-1 Antitrypsin Levels I #ats2026	HCPLive @hcplivenews	548	Estados Unidos	85
15	La Universitat se suma al Dia Europeu de Dèficit d'Alfa-1	Universitat de València @universitatvalencia	481	España	85
17	Inhaled Treprostinil for IPF: TETON-1 Phase 3 Results With Steven Nathan, MD \| ATS 2026	HCPLive @hcplivenews	301	Estados Unidos	85
6	Mixed AERIFY Data May Delay Itepekimab Approval Pathway in COPD, With Klaus F. Rabe, MD, PhD	HCPLive @hcplivenews	198	Estados Unidos	87
16	REACH Study: Broncho-Vaxom (OM-85) Cuts Recurrent Respiratory Tract Infections	HCPLive @hcplivenews	134	Estados Unidos	85
3	Tezepelumab Reduced Severe Asthma Exacerbations Across Phenotypes \| ATS 2026	HCPLive @hcplivenews	122	Estados Unidos	88
4	AERIFY: Phase 3 Data Reveal Challenges, Potential of Itepekimab in COPD	HCPLive @hcplivenews	105	Estados Unidos	88
14	Brensocatib, 1 Year Later: Who Benefits Most? \| Mark Metersky, MD	HCPLive @hcplivenews	98	Estados Unidos	85
20	Efdoralprin Alfa vs Standard of Care in AATD: Phase 2 ElevAATe Results	HCPLive @hcplivenews	82	Estados Unidos	84
9	SUNRISE: Tezepelumab Shows Meaningful OCS Reduction in Severe Asthma	HCPLive @hcplivenews	78	Estados Unidos	86
11	Higher Steroid Doses May Shorten AE-SARD-ILD Hospitalizations \| ATS 2026	HCPLive @hcplivenews	73	Estados Unidos	86
13	Dupilumab Doubled Asthma Remission Odds in Type 2 Asthma:	HCPLive @hcplivenews	71	Estados Unidos	85
8	ATS 2026 Asthma Updates: Tezepelumab, Dupilumab, OCS Reduction & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	70	Estados Unidos	86
5	Tezepelumab Cuts Severe Asthma Exacerbations 70% in Real-World Patients \| ATS 2026	HCPLive @hcplivenews	68	Estados Unidos	87
10	Can CSU Patients Achieve True Remission? BTK Inhibitors, Biomarker Barriers, & More \| EAC 2026	HCPLive @hcplivenews	58	Estados Unidos	86
12	ATS 2026 Pulmonology: AD109, Ralinepag, ALIS, Itepekimab & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	55	Estados Unidos	86
7	SGLT2 Inhibitors May Reduce COPD Readmissions I ATS 2026	HCPLive @hcplivenews	48	Estados Unidos	87
2	Pegtarazimod Cuts Oxygen Need in Hospitalized COPD Patients \| ATS 2026 \| Gerald Criner, MD	HCPLive @hcplivenews	29	Estados Unidos	90
19	Why Quality of Life Can't Take a Back Seat in ISM: Thanai Pongdee, MD, on New PIONEER Data	HCPLive @hcplivenews	27	Estados Unidos	84